Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc. (PacBio)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Status: Development stage enterprise. The company is commercializing its "PacBio RS" third-generation DNA sequencing platform but has not yet recognized revenue from product sales. Revenue to date consists solely of government research grants. Commercial shipments of the PacBio RS system began in April 2011.
Key Financial Metrics
| Metric (in thousands) | Q1 2011 | Q1 2010 |
|---|---|---|
| Grant Revenue | $270 | $545 |
| Net Loss | $(34,809) | $(30,325) |
| Net Loss Per Share (Basic/Diluted) | $(0.66) | $(48.97) |
| Operating Expenses | $35,237 | $30,819 |
| Cash and Cash Equivalents | $84,615 | $64,816 |
| Total Investments | $163,933 | $136,024 |
| Total Liquidity (Cash + Investments) | $248,548 | $200,840 |
| Inventory | $13,539 | $6,864 |
| Total Liabilities | $29,887 | $25,881 |
| Accumulated Deficit | $(366,976) | $(332,167) |
Note: The filing does not provide gross margin or operating margin percentages as the company has no product revenue.
Material Changes vs. Prior Period
- Revenue: Decreased 50% to $270,000 due to a reduction in work performed under government grants.
- Operating Expenses: Increased 14% to $35.2 million.
- R&D: Decreased 5% to $24.1 million, driven by lower supply costs, partially offset by increased headcount for pre-production manufacturing.
- Sales, General & Administrative (SG&A): Increased 102% to $11.1 million, driven by higher personnel costs, professional fees for public company compliance, and promotional spending for the commercial launch.
- Liquidity: Total cash and investments increased to $248.5 million from $200.8 million in the prior year, reflecting the October 2010 IPO proceeds. However, cash and cash equivalents decreased from $147.7 million to $84.6 million during the quarter due to operating cash burn and net investment purchases.
- Inventory: Doubled to $13.5 million as the company invested $6.7 million in commercial inventories (instruments and consumables) in anticipation of the April 2011 launch.
Outlook, Risks, and Management Commentary
- Commercial Launch: The company began shipping commercial PacBio RS systems in North America in April 2011. As of March 31, 2011, the backlog was approximately $28.0 million (44 systems), expected to be delivered by December 31, 2011.
- Liquidity Outlook: Management believes existing cash and investments ($248.5 million) are sufficient to fund operations for at least 12 months. Future financing may be required if product revenue is insufficient.
- Legal Proceedings:
- Helicos Biosciences: Named as a defendant in a patent infringement suit. The USPTO has ordered re-examination of the asserted patents and rejected all claims as unpatentable over prior art as of April 13, 2011. No liability has been recorded.
- Life Technologies: A patent interference decision by the USPTO Board canceled Life Technologies' claims. Life Technologies has filed a complaint in District Court seeking review of this decision.
- Key Risks:
- CEO Hugh Martin has been diagnosed with multiple myeloma; while currently not impacting performance, future leadership continuity is a risk.
- Manufacturing complexity and low yields for consumable kits (SMRT Cells) may impact costs and supply.
- Dependence on third-party suppliers for critical components (semiconductors, optics, lasers).
- Significant accumulated deficit of $367 million; profitability is not expected in the near term.
Investor Verification Checklist
- Revenue Recognition Timing: Verify when revenue from the $28 million backlog will be recognized, noting that prior limited production units required upgrades before revenue could be booked.
- Manufacturing Yields: Assess the company's ability to scale production of SMRT Cells and consumables to meet demand at commercially viable costs.
- Legal Resolution: Monitor the status of the Helicos and Life Technologies litigation to ensure no injunctions or damages impact operations.
- Cash Burn Rate: Track quarterly operating cash burn (approx. $33.5 million in Q1 2011) against the $248.5 million liquidity runway.
- CEO Health: Monitor disclosures regarding the CEO's health and any potential succession planning.